Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its innovative TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © February 2025 Ascendis Pharma A/S.
Investor Contacts:Scott SmithAscendis Pharmair@ascendispharma.com
Media Contact:Melinda BakerAscendis Pharma+1 (650) 709-8875media@ascendispharma.com
Patti BankICR Healthcare+1 (415) 513-1284patti.bank@icrhealthcare.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Why Tesla Stock Soared This Week
Tesla CEO Elon Musk apologized for some of his comments last week that have weakened his relationship with the White House, boosting the stock. However, the reported launch of Tesla robotaxis in Austin, Texas, has been delayed to later this month. The company's declining sales are a major concern. These 10 stocks could mint the next wave of millionaires › Shares of Tesla (NASDAQ: TSLA) are up this week, climbing 10.3% as of market close on Friday. The rise came as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both sank modestly. Tesla stock recovered this week after the public spat between CEO Elon Musk and President Trump cooled. Last week, Musk and Trump found themselves in a very public spat. What began as criticism of Trump's flagship "Big, Beautiful Bill" escalated into personal attacks and serious accusations. Musk deleted his most incendiary post and apologized on X, saying that some of his posts last week had gone "too far." The de-escalation of the situation sent Tesla stock higher. The stock was also on the rise this week in anticipation of Tesla's reported robotaxi launch. According to a report from Bloomberg, Tesla was set to begin operating its vehicles autonomously in Austin, Texas, on June 12. However, it's now clear that the company has pushed back this date, now targeting June 22. Despite the delay, Tesla shares were up further on Friday. This is not the first time the company has failed to meet a target launch date or milestone for its autonomous driving technology. Musk previously said he was "very confident predicting" that there would be 1 million of his robotaxis on the roads no later than "next year" -- in 2019. I am dubious of the company's ability to deliver on its promises, and given the state of its current vehicle sales (which are seeing massive declines), I think this stock is extremely overvalued. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $376,048!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,816!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $655,255!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Why Tesla Stock Soared This Week was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
MGP Ingredients (NASDAQ:MGPI) investors are sitting on a loss of 68% if they invested three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term MGP Ingredients, Inc. (NASDAQ:MGPI) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 69% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 61% in the last year. More recently, the share price has dropped a further 10% in a month. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). MGP Ingredients saw its EPS decline at a compound rate of 54% per year, over the last three years. This fall in the EPS is worse than the 32% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. This positive sentiment is also reflected in the generous P/E ratio of 57.06. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on MGP Ingredients' earnings, revenue and cash flow. MGP Ingredients shareholders are down 60% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for MGP Ingredients you should be aware of. MGP Ingredients is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
3 hours ago
- Yahoo
Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller
Beaverton, Oregon-based semiconductor startup AheadComputing, founded by four former Intel (NASDAQ:INTC) central processing unit architects, announced in February that it secured $21.5 million in seed funding to develop a new class of high-performance processors based on the RISC-V architecture. The seed funding round was led by Eclipse Ventures, with participation from Maverick Capital, Fundomo, and EPIQ Capital. The company also added Jim Keller to its board of directors. Keller is widely regarded as one of the foremost chip designers in the world, having held engineering leadership roles at Apple (NASDAQ:AAPL), Advanced Micro Devices (NASDAQ:AMD), Intel, and Tesla (NASDAQ:TSLA), The Oregonian reports. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can The company, established in 2024, is aiming to design a scalable and power-efficient CPU that challenges x86 dominance in the data center and artificial intelligence sectors, The Oregonian says. Led by CEO Debbie Marr, AheadComputing intends to deliver what it calls the 'biggest, baddest CPU in the world.' RISC-V, a royalty-free, open instruction set architecture, is emerging as a credible alternative to proprietary platforms such as Intel's x86 and ARM's licensed designs. According to The Oregonian, the architecture enables companies to create customized processors without licensing restrictions or vendor lock-in. AheadComputing's team has grown to 80 employees, many of whom previously held senior roles at Intel. The company is targeting high-performance workloads in cloud infrastructure, AI inference, and edge computing applications. Its design leverages the modular 'chiplet' model, allowing for flexible system-on-chip configurations tailored to specific customer needs, The Oregonian reports. Trending: Invest where it hurts — and help millions heal:. Co-founder Jonathan Pearce told The Oregonian that the fragmentation of computing systems presents an opportunity for specialized vendors to offer optimized components within larger heterogeneous systems. 'You get the opportunity for a company like AheadComputing to provide that piece of the overall system. As opposed to the past 20 years where it was just one tech giant,' Pearce said. AheadComputing operates as a fabless semiconductor company, outsourcing chip fabrication to partners such as Taiwan Semiconductor Manufacturing Co. This capital-efficient model allows the firm to focus resources on architectural innovation and design execution, The Oregonian reports. Intel's long-standing position as Oregon's largest private employer is undergoing transition, with multiple senior engineers departing to build independent ventures. According to The Oregonian, AheadComputing represents one of the most ambitious spinouts, combining advanced design experience with startup agility. Vice president of AheadComputing's design verification Alon Mahl said the hands-on startup environment allows engineering leaders to accelerate timelines and make immediate decisions without layers of corporate oversight. The Oregonian says that the team is already seeking larger office space in Washington County to accommodate growth and additional equipment to The Oregonian, AheadComputing joins a small group of Oregon-based chip startups led by Intel alumni, including Ampere Computing, which was recently acquired by SoftBank for $6.5 billion while retaining its Portland office footprint. Portland State University professor Christof Teuscher, an expert in microprocessor architecture, said the startup is taking a high-risk, high-reward approach. While RISC-V has traditionally been used in academic and embedded contexts, The Oregonian says that Teuscher expressed skepticism about its ability to succeed in high-performance commercial environments. According to The Oregonian, AheadComputing envisions its chips will eventually power PCs, laptops, and data centers, with possible clients including Google, Amazon (NASDAQ:AMZN), and Samsung. Read Next: Here's what Americans think you need to be considered wealthy. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
